Accelerating the Path to a Healthier World

Bringing together pharmaceutical companies to share & validate safety testing methods

Explore our programs to learn more:

Developing data solutions for scientific research

Explore our programs to learn more:

Creating and testing Alzheimer’s disease tools to facilitate drug development

Explore our programs to learn more:

Accelerating the development of new, safe, & highly effective tuberculosis treatment regimens

Explore our programs to learn more:

Supporting collaborative research through shared data access and development of drug development tools

Explore our programs to learn more:

Assessing signs and symptoms of asthma severity in pediatric patients

Explore our programs to learn more:

Developing a harmonized, consensus-defined myelofibrosis symptom assessment questionnaire to use as a clinical trial endpoint measure

Explore our programs to learn more:

Developing standards for assessing outcomes in clinical trials of MS therapies

Explore our programs to learn more:

Collaborating to develop instruments that measure the patient’s perspective

Explore our programs to learn more:

Identifying patients with Parkinson’s disease before symptoms are apparent

Explore our programs to learn more:

Promoting research to discover treatments that improve the lives of PKD patients

Explore our programs to learn more:

Working with the FDA and medical product firms to assess patient outcomes

Explore our programs to learn more:

Developing and qualifying PRO instruments with the FDA for use in clinical trials

Explore our programs to learn more:

Bringing together experts with a range of skills to explore how patients view their therapy

Explore our programs to learn more:

Qualifying instruments for use in clinical trials to evaluate treatment benefit

Explore our programs to learn more:

Enriching our understanding of the effect of interventions on how patients feel and function

Explore our programs to learn more:

Creating

Consensus Science

C-Path orchestrates the sharing of data, expertise and knowledge among industry, regulatory authorities, government, patient advocacy groups and academia in the pre-competitive space to generate the evidence needed to improve the drug development pathway.

Read More

Defining

Paths

C-Path’s consensus science improves medical product development efficiencies by identifying pathways that integrate new scientific advances into the regulatory review process.

Read More

Improving

Global Health

The failure rate of testing new drug therapies is an astounding (and unacceptable) 95 %. Even worse, many of the failures occur during late-phase testing – after the bulk of research dollars have already been committed.

Read More

drug development timeline
accelerated timeline
Industry
Academia
Regulatory
Agencies

“C-Path has created neutral ground that allows FDA scientists to work collaboratively with industry and academic partners on improving the process.”

Janet Woodcock, MD, FDA